KRYS
Krystal Biotech, Inc.
NASDAQ · USHealthcareBiotechnology
$339.22-4.41%
Price as of Jul 20, 2026
KRYS financials
Krystal Biotech, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $389.1M | $290.5M | $50.7M | $0.00 |
| Cost of revenue | $28.8M | $20.1M | $3.1M | $0.00 |
| Gross profit | $360.4M | $270.5M | $47.6M | $0.00 |
| Operating expenses | $199.1M | $204.8M | $157.3M | $145.2M |
| Operating income | $161.3M | $65.7M | -$109.7M | -$145.2M |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M |
| EBITDA | $196.0M | $109.9M | -$91.3M | -$116.8M |
| Basic EPS | $7.08 | $3.12 | $0.40 | $-5.49 |
| Diluted EPS | $6.84 | $3.00 | $0.39 | $-5.49 |
| Balance sheet | ||||
| Cash & equivalents | $496.3M | $344.9M | $358.3M | $161.9M |
| Total assets | $1.3B | $1.1B | $818.4M | $558.5M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M |
| Stockholders’ equity | $1.2B | $946.4M | $778.6M | $522.2M |
| Total debt | $9.3M | $7.3M | $8.1M | $8.9M |
| Net debt | -$487.0M | -$337.6M | -$350.2M | -$153.0M |
| Cash flow | ||||
| Operating cash flow | $200.9M | $123.4M | -$88.8M | -$100.6M |
| Capital expenditure | -$12.0M | -$4.2M | -$11.8M | -$53.0M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |